Submission of Investor presentation
GEMAROMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gem Aromatics Ltd reported Q4FY26 standalone revenue of Rs 112 Cr, up 34% QoQ despite a 45.6% YoY decline. The company achieved sequential improvement in margins with gross margin recovering to 23.4% (from 18.4% in Q3) and EBITDA margin to 13.4% (from 9.1%), driven by better price realization, improved volumes, and operating leverage. Consolidated PAT turned positive at Rs 1 Cr from a loss of Rs 5 Cr in Q3, though profitability was impacted by Rs 9 Cr higher depreciation from Dahej capex capitalization. Commercial production of GEM Cool 5 and Safranal commenced at Dahej on 26 Feb 2026. However, the phenol derivatives business faces near-term headwinds from elevated phenol prices and supply volatility due to geopolitical issues. Total debt reduced significantly from Rs 224 Cr to Rs 150 Cr, while the company expanded capacity to 16,171 MTPA across three facilities.
The sequential recovery in margins and return to profitability are positive signals, though year-on-year comparisons remain weak. The Dahej facility ramp-up and new product launches should support future growth, but phenol supply risks and high depreciation may continue to weigh on consolidated earnings near-term.